Scholarlink

Background <p>Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with unmet clinical treatment needs, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promising therapeutic potential. This study systematically evaluated the efficacy of GLP-1 RAs in treating adult MASH patients via a meta-analysis of randomized controlled trials (RCTs).</p> Methods <p>Following PRISMA 2020 guidelines, we retrieved RCTs from PubMed, Embase, Cochrane Library and Web of Science. Eligible studies included adult MASH patients treated with GLP-1 RAs vs. placebo/standard care. Two reviewers independently performed literature screening, data extraction and risk-of-bias assessment (RoB 2.0). Meta-analysis was conducted using RevMan 5.4, with subgroup analyses by GLP-1 RA type and intervention duration. </p> Results <p>A total of 27 RCTs involving 2,687 patients were included. GLP-1 RAs significantly increased MASH resolution without fibrosis worsening (RR = 2.56; 95% CI, [1.90, 3.44]; <i>p</i> &lt; 0.00001; I<sup>2</sup> = 49%) and liver fibrosis improvement without steatohepatitis worsening (RR = 1.37; 95% CI, [1.06, 1.78]; <i>p</i> = 0.02; I<sup>2</sup> = 44%). Subgroup analyses showed GLP-1 RAs benefited MASH resolution across subgroups, while fibrosis improvement was only significant for multi-receptor agonists and intervention &gt; 48&#xa0;weeks. No significant changes in ALT/AST were observed (<i>p</i> &gt; 0.05). </p> Conclusions <p>GLP-1 receptor agonists are effective for achieving histological remission in MASH. More large-scale, long-term follow-up randomized controlled trials are urgently needed.</p> <p><i>Trial registration</i> The protocol for our meta-analysis and systematic review was registered and recorded in PROSPERO (registration no. CRD420261287573).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2026年7月27日

查看全文
  • Shi-ping Sun,
  • Chen-xi Wang,
  • Ming-kai Yuan,
  • Han Min

摘要

Background

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with unmet clinical treatment needs, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promising therapeutic potential. This study systematically evaluated the efficacy of GLP-1 RAs in treating adult MASH patients via a meta-analysis of randomized controlled trials (RCTs).

Methods

Following PRISMA 2020 guidelines, we retrieved RCTs from PubMed, Embase, Cochrane Library and Web of Science. Eligible studies included adult MASH patients treated with GLP-1 RAs vs. placebo/standard care. Two reviewers independently performed literature screening, data extraction and risk-of-bias assessment (RoB 2.0). Meta-analysis was conducted using RevMan 5.4, with subgroup analyses by GLP-1 RA type and intervention duration.

Results

A total of 27 RCTs involving 2,687 patients were included. GLP-1 RAs significantly increased MASH resolution without fibrosis worsening (RR = 2.56; 95% CI, [1.90, 3.44]; p < 0.00001; I2 = 49%) and liver fibrosis improvement without steatohepatitis worsening (RR = 1.37; 95% CI, [1.06, 1.78]; p = 0.02; I2 = 44%). Subgroup analyses showed GLP-1 RAs benefited MASH resolution across subgroups, while fibrosis improvement was only significant for multi-receptor agonists and intervention > 48 weeks. No significant changes in ALT/AST were observed (p > 0.05).

Conclusions

GLP-1 receptor agonists are effective for achieving histological remission in MASH. More large-scale, long-term follow-up randomized controlled trials are urgently needed.

Trial registration The protocol for our meta-analysis and systematic review was registered and recorded in PROSPERO (registration no. CRD420261287573).